Shilpa Medicare Ltd Share Price

📊 COMPANIES WITH STRONG RESULTS (NEHA GUPTA SEBI RA)

📊 COMPANIES WITH STRONG RESULTS 1️⃣ Power, Electrical & Energy POLYCAB • SIEMENS • POWERINDIA • APARINDS • TDPOWERSYS • PREMIERENE • QPOWER

2️⃣ Automobile & Auto Components BAJAJ-AUTO • TVSMOTOR • CRAFTSMAN • SJS • ATHERENERG • GNA • MTARTECH 3️⃣ Jewellery & Precious Metals TITAN • KALYANKJIL • BLUESTONE • PNGJL • SKYGOLD • PNGSREVA 4️⃣ IT, AI & Digital Technology NETWEB • E2E • TATATECH • HFCL • SYRMA • CYIENTDLM • STLTECH 5️⃣ Pharma & Life Sciences LAURUSLABS • GLAND • SAILIFE • NAVINFLUOR • NEULANDLAB • AARTIPHARM • SHILPAMED 6️⃣ Banking, NBFC & Financial Services ICICIBANK • IDFCFIRSTB • SHRIRAMFIN • CHOLAFIN • FEDERALBNK • LTF • POONAWALLA 📌 Strong results ≠ automatic buy. Always evaluate valuation, growth, risk & market conditions before taking any investment decision. #StockMarket #IndianStocks #NSE #BSE #Stocks #Investing #StockMarketIndia #Results #Earnings #SwingTrading

See More

Shilpa Medicare SWOT Analysis BY AASHISH

Strengths Strong growth in FY2025-26: Consolidated operating revenue increased to ₹1,538.87 crore, compared with ₹1,286.43 crore in FY2024-25. Consolidated PAT increased to ₹226.20 crore from ₹79.56 crore. Diversified pharmaceutical portfolio: Shilpa Medicare operates across APIs, formulations, biologics/biosimilars and CDMO/licensing, reducing dependence on a single product category. In FY25, formulations revenue increased 52.56%, while CDMO/licence-fee revenue increased 38.76%. Weaknesses High dependence on pharmaceutical R&D and regulatory approvals: Biosimilars and new products require significant development expenditure, clinical validation and regulatory approvals. API revenue pressure: FY25 API revenue declined 7.68% to ₹674.11 crore, even though formulations and CDMO revenues grew. Complex operating structure: The business spans APIs, formulations, biologics and CDMO activities, requiring substantial technical, regulatory and manufacturing capabilities. Opportunities Biosimilar expansion: Increasing adoption of biosimilars globally provides an opportunity for Shilpa Medicare to expand its biologics portfolio. New product launches: Planned products such as Aflibercept and expansion of Adalimumab into additional markets could support future growth. opportunities. Pipeline development: Investments in biosimilars and Phase III trials for Recombinant Human Albumin (rHA) in India and the EU provide longer-term growth potential. Threats Regulatory risk: Delays or failures in regulatory approvals for APIs, formulations or biosimilars could affect product launches and expected revenues. Pricing pressure: Competition in generic APIs and formulations can put pressure on selling prices and margins. Raw-material volatility: Changes in input costs can affect profitability.

See More

Stocks With Strong Future Guidance — Worth Tracking

• V-Marc • RR Kabel • Finolex • HFCL

• E2E Networks • MTAR Technologies • Syrma SGS • Netweb Technologies • Sterlite Technologies • Sansera Engineering • Azad Engineering • Omnitech Engineering • Dynamatic Technologies • Aequs • Rossell Techsys • Sona BLW • TD Power Systems • Ramkrishna Forgings • Happy Forgings • Shivalik Bimetal Controls • KSH International • Gland Pharma • Aarti Pharmalabs • Kwality Pharmaceuticals • Sudeep Pharma • Hitachi Energy India • Neogen Chemicals • Quality Power • Ather Energy • Sky Gold • Cupid • Sai Life Sciences • Electronics Mart India • Neuland Laboratories • Shilpa Medicare • Laurus Labs • Shadowfax Technologies • Sedemac Mechatronics • Siemens Energy India • Premier Energies • Navin Fluorine • Mold-Tek Technologies • Muthoot Microfinance • SJS Enterprises • Lloyds Engineering Works • Garware Hi-Tech Films • Universal Cables • Kalyan Jewellers • Bluestone Jewellery • P N Gadgil & Sons • TVS Motor • Bajaj Auto • Paytm • Eternal • IDFC First Bank • PNGS Reva Diamond Jewellery • Craftsman Automation • Apcotex Industries • Timex Group India • Deep Industries • Cholamandalam Investment & Finance • Equitas Small Finance Bank • Acutaas Chemicals • Apar Industries • CreditAccess Grameen • Lodha Developers • Shriram Finance • Sakar Healthcare • Rajratan Global Wire • Fineotex Chemical • Thyrocare Technologies • Ujjivan Small Finance Bank • Emmvee Photovoltaic Power • Gandhar Oil Refinery • NTPC Green Energy • Titan Company • Cyient DLM • Polycab India • Hindusthan Urban Infrastructure • Mahindra & Mahindra Financial Services • Huhtamaki India • Adani Energy Solutions • Dynamic Cables • Beta Drugs • Shyam Metalics & Energy • Anand Rathi Wealth • Prime Cable Industries • Groww • Landmark Cars • ICICI Bank • Bhansali Engineering Polymers • Poonawalla Fincorp • Jayaswal Neco Industries • Tatva Chintan Pharma Chem • Navkar Corporation • Federal Bank • Jio Financial Services • RBL Bank • L&T Finance • V2 Retail • SG Finserve

See More

Top Stocks to Watch: Shilpa Medicare, Silver Touch, Rashi Peripherals #shorts

Top Stocks to Watch: Shilpa Medicare, Silver Touch, Rashi Peripherals #shorts

Top Stocks to Watch: Shilpa Medicare, Silver Touch, Rashi Peripherals #shortsTop Stocks to Watch: Shilpa Medicare, Silver Touch, Rashi Peripherals #shorts

See More

Technical Analysis Shilpa Medicare

The stock

is in a strong uptrend consistently forming higher highs and higher lows over the past few months. The stock has delivered a sharp rally from lower levels and recently witnessed a strong breakout with a high-volume bullish candle indicating aggressive buying interest. Although the stock has become stretched in the short term the overall trend remains firmly positive. The recent breakout suggests strong momentum but after such a vertical move some profit booking or sideways consolidation is normal before the next leg higher. As long as the stock holds above its breakout zone the bullish structure remains intact. The immediate support is placed around ₹680–690 which is the recent breakout area and is likely to attract buying on declines. A stronger support zone is visible near ₹640–650 and a break below this level could weaken the short-term trend. On the upside the stock is trading near its recent high with the next resistance around ₹750–760. A strong close above this zone could extend the rally towards ₹800–830. The stock has a strong bullish technical outlook. Existing investors can continue to hold while maintaining a trailing stop-loss below ₹680. Fresh buying is better considered on a pullback towards the support zone or after a sustained breakout above ₹760 with strong volume. Long-term trend remains positive unless the price falls below ₹640.

See More